» Articles » PMID: 31405320

Cognitive Impairments in HCV Infection: From Pathogenesis to Neuroimaging

Overview
Publisher Routledge
Date 2019 Aug 14
PMID 31405320
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Extrahepatic manifestations of hepatitis C virus (HCV) infection, in particular cognitive impairments, can be present in the absence of clinical liver dysfunction. Executive memory, attention, and concentration are cognitive domains that are most frequently affected. Microstructural and functional changes in cortical gray matter and basal ganglia associate these neuropsychiatric changes in early HCV infection. No study has covered the relationship between imaging features of HCV-related cognitive impairment and HCV pathology. Herein we summarize evidence suggesting a direct pathology of HCV in microglia, astrocytes, and microvascular endothelial cells, and a neuroinflammatory response in HCV-related cognitive decline. Lipoproteins and their receptors mediate HCV infectivity in the central nervous system and confer susceptibility to HCV-related cognitive decline. Magnetic resonance spectroscopy has revealed changes compatible with reactive gliosis and microglial activation in basal ganglia, frontal and occipital white matter, in the absence of cirrhosis or hepatic encephalopathy. Similarly, diffusion imaging shows evidence of structural disintegrity in the axonal fibers of white matter tracts associated with temporal and frontal cortices. We also discuss the cognitive benefits and side-effects of the two most popular therapeutic protocols interferon-based therapy and interferon-free therapy using direct acting anti-virals. Evidences support a network-based pattern of disruption in functional connectivity in HCV patients and a common neuronal substrate for HCV-related and interferon-therapy-associated cognitive decline. These evidences might help identify patients who benefit from either interferon-based or interferon-free treatment regimen.

Citing Articles

Association between herpes zoster and Parkinson's disease and dementia: a systematic review and meta-analysis.

Zhang Y, Liu W, Xu Y Front Neurol. 2024; 15:1471736.

PMID: 39703359 PMC: 11655326. DOI: 10.3389/fneur.2024.1471736.


Improved cognition after rifaximin treatment is associated with changes in intra- and inter-brain network functional connectivity.

Casanova-Ferrer F, Gallego J, Fiorillo A, Urios A, Rios M, Leon J J Transl Med. 2024; 22(1):49.

PMID: 38217008 PMC: 10787503. DOI: 10.1186/s12967-023-04844-7.


Cognitive Performance in Asymptomatic Elderly People with Hepatitis C: The Role of Education.

Fakoury M, Schmidt S, Brandao Mello C, do Carmo Filho A, Amendola Pires M J Clin Med. 2023; 12(14).

PMID: 37510703 PMC: 10380825. DOI: 10.3390/jcm12144588.


Infectious diseases and cognition: do we have to worry?.

Hernandez-Ruiz V, Letenneur L, Fulop T, Helmer C, Roubaud-Baudron C, Avila-Funes J Neurol Sci. 2022; 43(11):6215-6224.

PMID: 35867217 PMC: 9305033. DOI: 10.1007/s10072-022-06280-9.


DYT- Mutation P222L Enhances PACT's Stimulatory Activity on Type I Interferon Induction.

Vaughn L, Frederick K, Burnett S, Sharma N, Bragg D, Camargos S Biomolecules. 2022; 12(5).

PMID: 35625640 PMC: 9138762. DOI: 10.3390/biom12050713.